ReviewNMR in biomedicine2022
Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.
Review in NMR in biomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- A Comparison of PET Tracers in Recurrent High-Grade Gliomas: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Preoperative assessment of recurrence-prone subregions within the peritumoral region of glioblastoma: a comparison between diffusion kurtosis and diffusion tensor imaging.Quantitative imaging in medicine and surgery · 2026Article
- Differentiating tumor recurrence and pseudoprogression in postoperative gliomas using pseudo-continuous arterial spin labeling (pCASL) technique.BMC medical imaging · 2025Article
- A self-supervised multimodal deep learning approach to differentiate post-radiotherapy progression from pseudoprogression in glioblastoma.Scientific reports · 2025Article
- Response Assessment in Long-Term Glioblastoma Survivors Using a Multiparametric MRI-Based Prediction Model.Brain sciences · 2025Article
- Modernizing Neuro-Oncology: The Impact of Imaging, Liquid Biopsies, and AI on Diagnosis and Treatment.International journal of molecular sciences · 2025Review
- Enhancement of the nontumor component in newly diagnosed glioblastoma as a more accurate predictor of local recurrence location: a multicenter study.Quantitative imaging in medicine and surgery · 2025Article
- Self-Assembled Nanoplatform with pH/NIR Light-Responsive Drug Delivery for Combined Therapy of Glioma in vitro.International journal of nanomedicine · 2025Article
- Radiogenomics as an Integrated Approach to Glioblastoma Precision Medicine.Current oncology reports · 2024Review
- A histogram of [EJNMMI research · 2024Article
- Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know.Journal of neurosurgery · 2023Review
- Article
- Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.Journal of translational medicine · 2023Article
- Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma.Pharmaceutics · 2023Review
- Radiomics analysis of amide proton transfer-weighted and structural MR images for treatment response assessment in malignant gliomas.NMR in biomedicine · 2023Article
- Imaging Findings ofNuclear medicine and molecular imaging · 2022Article
- Tumor Progression and Treatment-Related Changes: Radiological Diagnosis Challenges for the Evaluation of Post Treated Glioma.Cancers · 2022Review
- Editorial: Structural, Metabolic, and Physiologic MR Imaging to Study Glioblastomas.Frontiers in neurology · 2022Article
- Unsupervised learning of metabolic fingerprints from 3D magnetic resonance spectroscopic imaging enables glioma subtype classification.Neuro-oncology advancesArticle
- Distinction of pseudoprogression from true progression in glioblastomas using machine learning based on multiparametric magnetic resonance imaging and ONeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
Pseudoprogression (PsP) refers to treatment-related clinico-radiologic changes mimicking true progression (TP) that occurs in patients with glioblastoma (GBM), predominantly within the first 6 months after the completion of surgery and concurrent chemoradiation therapy (CCRT) with temozolomide. Accurate differentiation of TP from PsP is essential for making informed decisions on appropriate therapeutic intervention as well as for prognostication of these patients. Conventional neuroimaging findings are often equivocal in distinguishing between TP and PsP and present a considerable diagnostic dilemma to oncologists and radiologists. These challenges have emphasized the need for developing alternative imaging techniques that may aid in the accurate diagnosis of TP and PsP. In this review, we encapsulate the current state of knowledge in the clinical applications of commonly used metabolic and physiologic magnetic resonance (MR) imaging techniques such as diffusion and perfusion imaging and proton spectroscopy in distinguishing TP from PsP. We also showcase the potential of promising imaging techniques, such as amide proton transfer and amino acid-based positron emission tomography, in providing useful information about the treatment response. Additionally, we highlight the role of "radiomics", which is an emerging field of radiology that has the potential to change the way in which advanced MR techniques are utilized in assessing treatment response in GBM patients. Finally, we present our institutional experiences and discuss future perspectives on the role of multiparametric MR imaging in identifying PsP in GBM patients treated with "standard-of-care" CCRT as well as novel/targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.